Metagenomi, Inc. (NASDAQ:MGX) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Metagenomi, Inc. (NASDAQ:MGXGet Free Report) have been given a consensus rating of “Moderate Buy” by the seven ratings firms that are currently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $16.67.

A number of analysts have weighed in on MGX shares. Chardan Capital restated a “buy” rating and issued a $15.00 target price on shares of Metagenomi in a research report on Wednesday, November 20th. HC Wainwright raised their price target on shares of Metagenomi from $7.00 to $14.00 and gave the company a “buy” rating in a research note on Tuesday, December 10th.

Check Out Our Latest Analysis on MGX

Hedge Funds Weigh In On Metagenomi

A number of hedge funds have recently bought and sold shares of the company. Nuveen Asset Management LLC bought a new position in Metagenomi during the fourth quarter worth $228,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Metagenomi by 338.7% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,193 shares of the company’s stock worth $55,000 after buying an additional 11,730 shares during the last quarter. Focus Partners Wealth bought a new position in Metagenomi during the fourth quarter worth $99,000. Bank of America Corp DE raised its stake in Metagenomi by 482.9% during the fourth quarter. Bank of America Corp DE now owns 21,113 shares of the company’s stock worth $76,000 after buying an additional 17,491 shares during the last quarter. Finally, Jane Street Group LLC bought a new position in Metagenomi during the fourth quarter worth $107,000.

Metagenomi Stock Performance

Shares of Metagenomi stock opened at $2.36 on Tuesday. Metagenomi has a fifty-two week low of $1.61 and a fifty-two week high of $12.50. The company’s 50 day moving average price is $3.01 and its two-hundred day moving average price is $2.64.

Metagenomi Company Profile

(Get Free Report

Metagenomi, Inc, a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases.

Read More

Analyst Recommendations for Metagenomi (NASDAQ:MGX)

Receive News & Ratings for Metagenomi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Metagenomi and related companies with MarketBeat.com's FREE daily email newsletter.